Published in Int J Hepatol on June 27, 2012
Selection tool alpha-fetoprotein for patients waiting for liver transplantation: How to easily manage a fractal algorithm. World J Hepatol (2015) 0.83
Serum peptidome patterns of hepatocellular carcinoma based on magnetic bead separation and mass spectrometry analysis. Diagn Pathol (2013) 0.82
HCC-ART score, a simple, highly sensitive and specific test for early diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Br J Cancer (2013) 0.82
Comparison of Salvage Living Donor Liver Transplantation and Local Regional Therapy for Recurrent Hepatocellular Carcinoma. World J Surg (2016) 0.78
Alpha-fetoprotein level as a biomarker of liver fibrosis status: a cross-sectional study of 619 consecutive patients with chronic hepatitis B. BMC Gastroenterol (2014) 0.78
Measurement of glycosylated alpha-fetoprotein improves diagnostic power over the native form in hepatocellular carcinoma. PLoS One (2014) 0.76
Disease monitoring of hepatocellular carcinoma through metabolomics. World J Hepatol (2017) 0.75
How to Improve Therapeutic Ratio in Radiotherapy of HCC. Liver Cancer (2016) 0.75
Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer. HPB (Oxford) (2015) 0.75
Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome. ISRN Hepatol (2014) 0.75
Predictors of recurrence in hepatitis C virus related hepatocellular carcinoma after hepatic resection: a retrospective cohort study. Eurasian J Med (2014) 0.75
The growing impact of alpha-fetoprotein in the field of liver transplantation for hepatocellular cancer: time for a revolution. Transl Gastroenterol Hepatol (2017) 0.75
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 16.93
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology (2001) 6.19
Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med (2003) 5.45
Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med (1993) 5.32
Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol (2008) 5.24
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol (2001) 4.46
EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res (2008) 4.17
Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet (2003) 3.93
Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res (2012) 3.39
New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol (2008) 2.65
Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl (2010) 2.57
Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology (2009) 2.51
Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation (2008) 2.48
Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39
Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl (2008) 2.22
The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol (2011) 2.12
Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol (2004) 2.10
Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl (2008) 2.04
Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant (2010) 1.93
Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg (2004) 1.88
Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. Gastroenterology (2009) 1.70
Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl (2008) 1.68
Cancer gene discovery in hepatocellular carcinoma. J Hepatol (2010) 1.68
Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark (2007) 1.65
Evaluation of absolute serum α-fetoprotein levels in liver transplant for hepatocellular cancer. Arch Surg (2011) 1.60
Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis (2007) 1.60
Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol (2007) 1.49
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer (2010) 1.48
A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma. Panminerva Med (2008) 1.46
AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol (2010) 1.44
AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer (2008) 1.37
Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol (2008) 1.37
Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant (2009) 1.27
Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl (2007) 1.27
Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol (2008) 1.26
Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl (2001) 1.25
Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci (2007) 1.24
Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol (2011) 1.20
Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol (2009) 1.19
Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China. J Cancer Res Clin Oncol (2009) 1.12
Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria. Dig Dis (2007) 1.11
Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol (2006) 1.11
Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl (2007) 1.10
Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transpl (2003) 1.08
Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J Gastroenterol (2007) 1.06
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer (2010) 1.06
PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology (2007) 1.04
Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study. J Clin Gastroenterol (2009) 1.01
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol (2012) 1.01
Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin. Liver Int (2010) 0.99
Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology (2006) 0.98
Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol (2007) 0.97
Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: the potential of gene expression profiling. Semin Liver Dis (2006) 0.94
Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer. Drug News Perspect (2010) 0.92
Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol (2008) 0.91
Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP. Hepatogastroenterology (2009) 0.87
Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol (2010) 0.87
Triple positive tumor markers for hepatocellular carcinoma are useful predictors of poor survival. Ann Surg (2011) 0.86
Clinical utility of prothrombin induced by vitamin K absence in the detection of hepatocellular carcinoma in Indian population. Hepatol Int (2010) 0.86
A new prognostic staging system for hepatocellular carcinoma: value of the biomarker combined Japan integrated staging score. Intervirology (2008) 0.85
Combination of biological and morphological parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation. Clin Transplant (2011) 0.83
HCC in living donor liver transplantation: can we expand the Milan criteria? Dig Dis (2007) 0.83
Role of blood AFP mRNA and tumor grade in the preoperative prognostic evaluation of patients with hepatocellular carcinoma. World J Gastroenterol (2005) 0.82
Preoperative tumor marker doubling time is a useful predictor of recurrence and prognosis after hepatic resection of hepatocellular carcinoma. J Surg Oncol (2010) 0.81
Fractional allelic imbalance could allow for the development of an equitable transplant selection policy for patients with hepatocellular carcinoma. Liver Transpl (2008) 0.81
High co-expression of vascular endothelial growth factor receptor-1 and Snail is associated with poor prognosis after curative resection of hepatocellular carcinoma. Med Oncol (2012) 0.81
Role of alpha-fetoprotein in selection of patients with hepatocellular carcinoma waiting for liver transplantation: must we reconsider it? Int J Biol Markers (2011) 0.81
α-fetoprotein, vascular endothelial growth factor receptor-1 and early recurrence of hepatoma. World J Gastroenterol (2012) 0.80
Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival. Dig Dis Sci (2011) 0.79
Predictive factors of recurrence of hepatocellular carcinoma after liver transplantation: a multivariate analysis. Transplant Proc (2009) 0.79
AFP in OLT for HCC?: Another shadow on the cave wall: Comment on "Evaluation of absolute serum α-fetoprotein levels in liver transplant for hepatocellular cancer". Arch Surg (2011) 0.79
The Milan criteria: no room on the metro for the king? Liver Transpl (2010) 0.79
Tumor markers after radiofrequency ablation therapy for hepatocellular carcinoma. Hepatogastroenterology (2008) 0.79
Postoperative changes in protein-induced vitamin K absence or antagonist II levels after hepatectomy in patients with hepatocellular carcinoma: relationship to prognosis. HPB (Oxford) (2006) 0.79
Some patients with HCC haven't abnornormal des-gamma-carboxy prothrombin and alpha-fetoprotein levels. Panminerva Med (2009) 0.78
Differential effects of vitamin K1 on AFP and DCP levels in patients with unresectable HCC and in HCC cell lines. Dig Dis Sci (2010) 0.78
Building a comprehensive genomic program for hepatocellular carcinoma. World J Surg (2011) 0.77
A prospective study of blood alpha-fetoprotein messenger RNA as a predictor of hepatocellular carcinoma in patients with cirrhosis. J Viral Hepat (2003) 0.76
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer. Transpl Int (2013) 2.53
Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl (2013) 2.09
Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis. Radiology (2010) 1.97
Multipotent stem/progenitor cells in human biliary tree give rise to hepatocytes, cholangiocytes, and pancreatic islets. Hepatology (2011) 1.94
Glial fibrillary acidic protein as an early marker of hepatic stellate cell activation in chronic and posttransplant recurrent hepatitis C. Liver Transpl (2008) 1.65
Human OX40 tunes the function of regulatory T cells in tumor and nontumor areas of hepatitis C virus-infected liver tissue. Hepatology (2014) 1.58
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis (2010) 1.54
Biliary tree stem/progenitor cells in glands of extrahepatic and intraheptic bile ducts: an anatomical in situ study yielding evidence of maturational lineages. J Anat (2011) 1.51
Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation (2004) 1.49
Feasibility and limits of split liver transplantation from pediatric donors: an italian multicenter experience. Ann Surg (2006) 1.43
Nutritional status: its influence on the outcome of patients undergoing liver transplantation. Liver Int (2009) 1.23
Renal transplant in methylmalonic acidemia: could it be the best option? Report on a case at 10 years and review of the literature. Pediatr Nephrol (2007) 1.16
Recurrence of hepatocellular cancer after liver transplantation: the role of primary resection and salvage transplantation in East and West. J Hepatol (2012) 1.14
Pregnancy after liver transplantation: report of 8 new cases and review of the literature. Transpl Immunol (2006) 1.01
A randomized controlled trial of IV immunoglobulin in patients with postpolio syndrome. J Neurol Sci (2013) 0.91
Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT. Radiology (2009) 0.90
[Surgical management of schwannoma of biliary tract]. Chir Ital (2009) 0.89
Predictive criteria for the outcome of patients with acute liver failure treated with the albumin dialysis molecular adsorbent recirculating system. Ther Apher Dial (2009) 0.88
Chronic kidney disease after liver transplantation: pretransplantation risk factors and predictors during follow-up. Transplantation (2013) 0.87
The bony labyrinth of Oreopithecus bambolii. J Hum Evol (2004) 0.85
Hepatocellular carcinoma in cirrhotic patients: prospective comparison of US, CT and MR imaging. Eur Radiol (2012) 0.85
Detection of hepatocellular carcinoma in patients with cirrhosis: added value of coronal reformations from isotropic voxels with 64-MDCT. AJR Am J Roentgenol (2009) 0.84
Retrorectal tumors: the choice of surgical approach based on a new classification. Am Surg (2009) 0.83
The short- and ultrashort-pedicle deep inferior epigastric artery perforator flap in breast reconstruction. Plast Reconstr Surg (2012) 0.83
Combination of biological and morphological parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation. Clin Transplant (2011) 0.83
Gadobenate dimeglumine-enhanced magnetic resonance imaging of primary leiomyoma of the liver. J Magn Reson Imaging (2008) 0.82
Acute hepatitis associated with lamotrigine and managed with the molecular adsorbents recirculating system (Mars). Epilepsia (2005) 0.82
Preharvest donor hyperoxia predicts good early graft function and longer graft survival after liver transplantation. Liver Transpl (2005) 0.82
Treatment of recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl (2011) 0.82
MuRF-1 and p-GSK3β expression in muscle atrophy of cirrhosis. Liver Int (2013) 0.82
Role of alpha-fetoprotein in selection of patients with hepatocellular carcinoma waiting for liver transplantation: must we reconsider it? Int J Biol Markers (2011) 0.81
Use of elderly donors for liver transplantation: has the limit been reached? J Gastrointestin Liver Dis (2011) 0.81
Effects of unilateral ovariectomy on female fertility outcome. Arch Gynecol Obstet (2014) 0.81
Inferior vena cava interruption in a liver transplantation deceased donor. Liver Int (2012) 0.81
Laparoscopy in Liver Transplantation: The Future has Arrived. HPB Surg (2012) 0.81
MARS (Molecular Adsorbent Recirculating System): experience in 34 cases of acute liver failure. Liver (2002) 0.80
A case of portal vein arterialization after a liver transplant. Exp Clin Transplant (2013) 0.80
The best approach for splenectomy in portal hypertension. Surgery (2011) 0.79
Transjugular intrahepatic portosystemic shunt for a wait list patient is not a contraindication for orthotopic liver transplant outcomes. Exp Clin Transplant (2013) 0.79
High preoperative recipient plasma 7beta-hydroxycholesterol is associated with initial poor graft function after liver transplantation. Liver Transpl (2005) 0.79
Multislice computed tomography in the preoperative assessment of adult-to-adult living donor liver transplantation: personal results. Radiol Med (2003) 0.78
Intrahepatic lymphatic invasion but not vascular invasion is a major prognostic factor after resection of colorectal cancer liver metastases. World J Surg (2014) 0.78
Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study. Antivir Ther (2011) 0.77
Liver transplantation in adults: Choosing the appropriate timing. World J Gastrointest Pharmacol Ther (2012) 0.77
Ethical considerations on kidney transplantation from living donors. Ann Transplant (2004) 0.76
Cystic presentation of a renal medullary carcinoma in a young woman. Urologia (2014) 0.76
Long-term effect of liver transplantation on cirrhotic autonomic cardiac dysfunction. Dig Liver Dis (2009) 0.76
Recipient perioperative cholesterolaemia and graft cholesterol metabolism gene expression predict liver transplant outcome. Liver Int (2013) 0.76
Parenchymal sparing operations for bronchogenic carcinoma. Surg Clin North Am (2002) 0.76
Strategies for evaluation of suitable donors: Italian experience. Ann Transplant (2004) 0.75
Failure of hepatitis B vaccination to induce either humoral or cellular immune response after liver transplantation for hepatitis B related cirrhosis. J Hepatol (2005) 0.75
Liver transplant using a severely lacerated graft treated by arterial embolization. Exp Clin Transplant (2013) 0.75
Split-liver transplantation with pediatric donors: a multicenter experience. Transplantation (2005) 0.75
Surgical margin size in hepatic resections for colorectal metastasis: impact on recurrence and survival. Arq Bras Cir Dig (2014) 0.75
TIPS for patients awaiting orthotopic liver transplantation. Liver Transpl (2003) 0.75
Bilateral ex vivo repair and kidney autotransplantation for complex renal artery aneurysms: a case report and literature review. Int J Urol (2013) 0.75
Hepatocellular carcinoma (HCC) in non-cirrhotic liver: clinical, radiological and pathological findings. Eur Radiol (2014) 0.75
A paragastric gossypiboma with caval thrombosis. Ann Vasc Surg (2010) 0.75
[Multimodal treatment for acute antibody-mediated renal transplant rejection: successful rescue therapy with combined plasmapheresis, photopheresis and intravenous immunoglobulin]. G Ital Nefrol (2012) 0.75
[Emergency surgery for colorectal cancer: our experience]. Chir Ital (2004) 0.75
[Adacolumn apheresis for hepatitis C virus in patients waiting for kidney transplant. Preliminary study]. G Ital Nefrol (2012) 0.75
Liver splenosis mimicking hepatocellular carcinoma in cirrhotic liver. Liver Int (2013) 0.75
Chylous Leakage After a Laparoscopic Live-Donor Nephrectomy: Case Report and Literature Review. Exp Clin Transplant (2015) 0.75
A 3-year experience with Molecular Adsorbent Recirculating System (MARS): our results on 63 patients with hepatic failure and color Doppler US evaluation of cerebral perfusion. Liver Int (2003) 0.75
Massive bleeding from a gastric varix coil migration in a liver transplant patient. J Gastrointestin Liver Dis (2013) 0.75
Which Is the True Role of Bridging Therapies for HCC Patients Waiting for Liver Transplantation? Ann Surg (2017) 0.75
Graft macrosteatosis and time of T-tube removal as risk factors for biliary strictures after liver transplantation. Clin Transplant (2013) 0.75
Portal vein thrombosis before liver transplant does not alter postoperative patient or graft survival. Exp Clin Transplant (2014) 0.75
Hybrid Partial ALPPS: a Feasible Approach in Case of Right Trisegmentectomy and Macrovascular Invasion. Ann Surg (2017) 0.75
Cerebral Lymphoma in a Kidney Transplant: A Case Report. Exp Clin Transplant (2015) 0.75